3hon MSN
Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...
Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took ...
Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
The diabetes startup is prescribing GLP-1 drugs for weight loss to help employers manage costs. Its CEO says it's nearing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback